Alpha Tau Medical Ltd. (DRTS)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Alpha Tau Medical: A Lot Of Shots On Goal
Alpha Tau Medical (DRTS) is pioneering localized alpha particle radiation for solid tumors, with strong recent clinical and partnership momentum. DRTS's innovative and patented "Alpha DaRT" technology overcomes prior range limitations and shows high response rates in multiple indications. This month's recent Tolmar partnership brings $35M in upfront capital and potential milestones, supporting DRTS's cash runway through 2027 amid ongoing trials.
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
Alpha Tau Medical NASDAQ: DRTS outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the company's most important trials are “coming to a head” over the coming months.
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
Alpha Tau Medical NASDAQ: DRTS presented early clinical results from the first three patients treated in its REGAIN study of Alpha DaRT for recurrent glioblastoma, with company executives and clinical investigators describing initial tumor responses and safety observations from the pilot trial.
Alpha Tau Medical Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Christoph Von Dem Bussche Financial Guidance Group Inc. | 20,000 | $78,931.45 | $266,400 | $187,468.55 | 237.51% |
 Sue Oleari Trifecta Capital Advisors LLC | 9,700 | $48,015 | $126,585 | $78,570 | 163.64% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 68 | $481 | $915.96 | $434.96 | 90.43% |
 Kevin Bresler TD Waterhouse Canada Inc. | 2,568 | $11,119 | $32,100 | $20,981 | 188.7% |
 Alan Gilmore Private Wealth Management Group, LLC | 752 | $5,317 | $9,400 | $4,083 | 76.79% |
Alpha Tau Medical Ltd. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LS Lukas Shumway Barclays | 2,467.92 | $25,000 | $28,504.44 | $3,504.44 | 14.02% |
Alpha Tau Medical Ltd. (DRTS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alpha Tau Medical Ltd. ever had a stock split?
Alpha Tau Medical Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Uzi Sofer CEO | NASDAQ (CM) Exchange | 55302T102 CUSIP |
| IL Country | 121 Employees | - Last Dividend | - Last Split | 8 Mar 2021 IPO Date |
Overview
Alpha Tau Medical Ltd. is a pioneering force in the field of oncology therapeutics, currently in the clinical-stage of developing a revolutionary treatment known as diffusing alpha-emitters radiation therapy (Alpha DaRT). With its focus on targeting solid cancers, the company's research and development efforts span across both Israel and the United States. Established in 2015 and having its headquarters in Jerusalem, Israel, Alpha Tau Medical Ltd. is committed to advancing the fight against cancer through its innovative approach to radiation therapy. By leveraging the unique properties of alpha-emitters, the company aims to provide new hope and solutions for patients battling various forms of solid tumors.
Products and Services
Alpha Tau Medical Ltd. is centered around its proprietary Alpha DaRT technology, which is currently being evaluated through clinical trials and preclinical studies for its efficacy in treating a wide range of solid tumors:
- Skin, Oral, Pancreatic, Prostate, Lung, Liver, and Breast Cancers: These are at the forefront of the company’s clinical trials utilizing Alpha DaRT technology, showcasing its versatility and potential in treating a diverse array of solid tumor types.
- Brain and Other Cancers: Alpha Tau Medical is extending its research to include preclinical or pending clinical studies for brain and various other forms of cancer, highlighting the expansive scope of Alpha DaRT's applicability and its potential to offer benefits across a broader spectrum of oncological challenges.
- Hepatic Cell Carcinoma, Glioblastoma Multiforme, Lung Cancer, and More: The company is also engaged in preclinical studies targeting these specific types of cancer, underscoring its commitment to exploring Alpha DaRT's effectiveness in combating even the most challenging and aggressive forms of solid tumors.
